Loading stock data…
SOLV
$82.46+3.70 (+4.70%)
After Hours$81.56-0.90 (-1.09%)· Last close Jun 9
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Solventum Corporation in the Healthcare sector is trading at $82.46. Wall Street consensus targets $82.15 (13 analysts), implying a -0.4% move over the next 12 months. The stock is currently 7% below its 52-week high of $88.20, remaining 11.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$82.46
Potential Downside
0%
Whystock Fair Value$82.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$82.15-0.4%
Range$60.00 – $100.00
Fundamentals
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Den...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
28.81%
Volume
Today's trading volume
1.41M
Recent News
1 Profitable Stock with Exciting Potential and 2 That Underwhelm
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Solventum Trends for 2026: AI Coding, Tariffs, and Margins
SOLV heads into 2026 balancing AI coding growth, cost savings, tariff pressure and a potential 2027 margin risk tied to its 3M supply deal.
Q1 Earnings Roundup: Solventum (NYSE:SOLV) And The Rest Of The Surgical Equipment & Consumables - Diversified Segment
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including Solventum (NYSE:SOLV) and its peers.
Is Solventum’s (SOLV) Governance Tweaks Hinting At How It Will Navigate AI Disruption?
In May 2024, a stockholder class action in Delaware challenged aspects of Solventum’s advance notice and nomination by-laws, which the company later amended before resolving the case as moot and agreeing to pay US$120,000 in attorneys’ fees without admitting wrongdoing. This outcome highlights how investor pressure over governance terms can prompt Solventum to adjust its corporate by-laws while balancing legal risk and cost. We’ll now examine how concerns about AI-driven disruption in...
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.